Cytokinetics

Cytokinetics Pre-Tax Margin

The Pre-Tax Profit Margin of Cytokinetics (CYTK) as of Nov 21, 2026 is -891.60 %. In the previous year, Pre-Tax Profit Margin was -3,191.11 % — a change of -72.06% (higher).

Pre-Tax Margin

-891.60 %

YoY

-72.06%

Last updated:

Pre-Tax Profit Margin of Cytokinetics is 2025 -891.60 % . Pre-Tax Profit Margin of Cytokinetics was 2024 -3,191.11 % . It decreases by -72.06% higher compared to the previous year.

The Cytokinetics Pre-Tax Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Pre-Tax Margin
Date
Pre-Tax Margin
Jan 1, 2018
-337.41 USD
Jan 1, 2019
-452.93 USD
Jan 1, 2020
-228.00 USD
Jan 1, 2021
-305.72 USD
Jan 1, 2022
-411.21 USD
Jan 1, 2023
-6,988.63 USD
Jan 1, 2024
-3,191.11 USD
Jan 1, 2025
-891.60 USD
The Cytokinetics Pre-Tax Margin history
YEARPre-Tax MarginYoY
-891.60 %-72.06%
-3,191.11 %-54.34%
-6,988.63 %+1,599.53%
-411.21 %+34.50%
-305.72 %+34.09%
-228.00 %-49.66%
-452.93 %+34.23%
-337.41 %-64.70%
-955.94 %-6,282.38%
15.46 %-111.82%
-130.86 %+319.39%
-31.20 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cytokinetics Stock analysis

What does Cytokinetics do? Cytokinetics Inc. is a biotechnology company that was founded in 1998 and is headquartered in South San Francisco, California. The company focuses on developing novel therapies for diseases of the nervous system, cardiovascular system, and muscles. Cytokinetics develops its drugs by identifying proteins and molecules that have potential for treating diseases. The company's business model is based on the development of therapies that target the improvement of muscle strength and function. Cytokinetics is known for its innovative drug classes such as myosin inhibitors and activators, as well as its novel drug CK-274. The company offers various products aimed at improving muscle strength and function, including CK-274, a myosin inhibitor currently in phase III development for the treatment of hypertrophic cardiomyopathy. Cytokinetics is also the developer of Omecamtiv Mecarbil, a myosin activator for the treatment of heart failure, and SMN2 splicing modulators for improving SMN protein synthesis in patients with spinal muscular atrophy. The company has established partnerships with leading pharmaceutical companies for the further development and commercialization of its drugs. With its innovative therapies and industry expertise, Cytokinetics has become one of the leading biotechnology companies in the United States focused on improving muscle strength and function. Cytokinetics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cytokinetics stock

Pre-Tax Profit Margin of Cytokinetics is -891.60 % in 2025.

Pre-Tax Profit Margin of Cytokinetics changed from -3,191.11 % to -891.60 %, representing a -72.06% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Pre-Tax Profit Margin Cytokinetics since 2006 – with annual values, charts, and detailed analysis.

Pre-tax margin measures the percentage of revenue remaining after all expenses except income taxes. It isolates operational and financial performance from tax effects.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Pre-Tax Profit Margin's Cytokinetics with sector peers and the industry average to assess whether it is attractive.

To evaluate Pre-Tax Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Pre-Tax Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Cytokinetics

All Key Metrics — Cytokinetics